Oral IL-1β Production Inhibitor

About Allinky Biopharma

Allinky Biopharma is a private, preclinical-stage biotech pioneering novel oral allosteric inhibitors for chronic inflammation and cancer. Its core innovation is a first-in-class oral inhibitor targeting the production of IL-1β, a key inflammatory mediator, with significant patents granted in the US, Europe, and China. The company is backed by venture capital and non-dilutive grants, having recently secured a €2M capital increase and a Seal of Excellence from the EU's EIC Accelerator, positioning it to advance its lead candidate towards clinical trials.

Therapeutic Areas